Detail akcie Harrow Health Rg online

Business Summary: Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Harrow Inc revenues increased 53% to $199.6M. Net loss decreased 28% to $17.5M. Revenues reflect Branded segment increase from $50.3M to $116.1M, ImprimisRx segment increase of 4% to $83.5M. Lower net loss reflects Impairment of long-lived assets decrease of 33% to $253K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.75 to -$0.49.